The EMA’s CHMP has adopted two positive opinions for Merck’s pembrolizumab (KEYTRUDA), potentially expanding its use in ...

A new Nature study suggests that the glucose–fructose blend typical of sodas and juices fuels colorectal cancer metastasis ...

A large clinical trial from Karolinska Institutet shows that daily low-dose aspirin can cut colorectal cancer recurrence risk ...

In the next 25 years, climate-driven health impacts could result in the loss of more than $1.5 trillion in lost output from ...

The third-generation tyrosine kinase inhibitor olverembatinib may represent a major advance for patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia, especially those with ...

The FDA has granted Breakthrough Therapy Designation to raludotatug deruxtecan (R-DXd), a novel antibody-drug conjugate (ADC) ...

It was truly exciting and a great pleasure to have the opportunity to interview Susanna Greer, CSO at the V Foundation, and ...

A $500,000 grant from the Cancer Vaccine Coalition, in partnership with The V Foundation, is set to expand UW Medicine’s WOKVAC Phase 2 clinical trial—one of the most advanced therapeutic breast ...

The V Foundation for Cancer Research and the Cancer Vaccine Coalition (CVC) have launched a first-of-its-kind partnership to speed the development of therapeutic breast cancer vaccines. In this ...

The new issue of ONCOLife is now available — featuring innovative advances, exclusive expert interviews, and the latest regulatory updates that are shaping the future of cancer treatment. With a focus ...

The FDA has granted Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren), a first-in-class bispecific ADC targeting EGFR and HER3, for advanced non-small cell lung cancer (NSCLC) ...

The first blood test, Lumipulse pTau-217/Aβ42, is now on the market for aiding Alzheimer’s diagnosis following FDA clearance for early detection of amyloid pathology. Developed by Fujirebio, the assay ...